On 10 September 2026, CHINA SHENGMU-PF (01432.HK) and Modern Dairy (01117.HK) published a joint announcement that the irrevocable voting proxy granted by Start Great to Modern Dairy partially lapses, covering 829,748,228 China Shengmu shares (approximately 9.90%), while the proxy over 1,257,194,284 shares (approximately 15.00%) remains in force; Modern Dairy is entitled to exercise voting rights over 5,743,913,630 shares (approximately 68.53%) including its post-offer holding, and together with concert parties approximately 83.52%. The announcement also warned of a severe public float shortfall at China Shengmu, whose listing will be cancelled if it fails to regain compliance with Rule 13.32B by 2 February 2028.
After trading hours on 10 September 2026, CWT INT'L (00521.HK) announced that its indirect wholly-owned subsidiary MRI Trading AG entered into a third sales contract with TMSC Trading for the purchase of 501 tonnes (plus or minus 5%) of LME-registered Grade A copper cathode originating from the Democratic Republic of the Congo, at a contract consideration of USD 7,452,090.08 (approximately HKD 58,126,302.62); TMSC Trading is an indirect subsidiary of controlling shareholder HNA Xinguan (holding approximately 51.26%), making the transaction a connected transaction aggregated with the second sales contract under Rule 14A.81, with applicable percentage ratios above 0.1% but below 5%, subject to reporting and announcement but exempt from circular and independent shareholders' approval.
On 10 September 2026, HIPINE (02583.HK) announced its September 2026 business initiatives, including co-initiating a "Smart Jewellery" group standard with National Technical Committee 256 on Jewellery Standardisation and Beijing Guoshou Jewelry Testing, launching a pure gold smart ring that obtained the industry's first dedicated certificate for such products, and a co-branded porcelain smart ring with Shenzhen Guoci Yongfengyuan; its subsidiary Shenzhen Jinling Artificial Intelligence also launched a jewellery store AI retail agent, with the company cautioning that commercialisation and market benefits remain uncertain.
On 10 September 2026, SIPAI HEALTH (00314.HK) announced that all conditions precedent under the share purchase agreement for the acquisition by its wholly-owned subsidiary Bixun Pharmaceutical of 100% equity interests in Shanze Technology and Jianyi Information Technology (Shanghai) Co., Ltd. were fulfilled, with completion taking place on 9 September 2026; the target companies became wholly-owned subsidiaries and their financial results, assets and liabilities will be consolidated from September 2026, following earlier announcements on 18 March and 13 April 2026.
On 10 September 2026, SHUNHO PROPERTY (00219.HK) announced that its public float of approximately 22.59% fell about 2.41 percentage points below the 25% minimum under Listing Rule 13.32B due to inadvertent oversight concerning shares without exercisable voting rights held via core connected persons, with non-compliance dating back to 8 December 2020; the company plans to restore the float within six months through disposals or placings by the Shun Ho Holdings subsidiaries and an independent investor and/or an issue of new shares under a general mandate, with monthly updates.
On 10 September 2026, WENGE AI (01956.HK) announced that the board lot for its H shares will be changed from 200 shares to 50 shares with effect from 9:00 a.m. on 2 October 2026; based on the closing price of HKD 77.65 per H share on the announcement date, a board lot was worth HKD 15,530 before the change and HKD 3,882.5 after, with the company citing greater trading convenience and market liquidity, and the free certificate exchange period running from 17 September to 27 October 2026.
On 10 September 2026, HENGRUI PHARMA (01276.HK) announced that the NMPA approved two additional indications for Hetrombopag Olamine Tablets, a Class 1 innovative drug, for adult patients with chemotherapy-induced thrombocytopenia (CTIT) and paediatric patients aged 6 and above with chronic primary immune thrombocytopenia (ITP), classified as a Category 2.4 chemical drug; the product becomes the world's first TPO-RA approved for CTIT, with cumulative R&D investment of approximately RMB 657.70 million (unaudited).
On 10 September 2026, SG GROUP HLDGS (01657.HK) announced proposals to change its English name to Sefon Holdings Limited and its Chinese dual foreign name to 四方偉業控股有限公司, and to subdivide each existing HKD 0.01 share into ten HKD 0.001 shares; upon effectiveness, authorised share capital will comprise 2,000,000,000 subdivided shares with 320,000,000 shares in issue, the board lot will remain 500 shares, and the subdivision is expected to take effect on 5 October 2026, subject to approval at an extraordinary general meeting on 30 September 2026.
On 10 September 2026, REALORD TECH (01196.HK) announced that Mr. Tsang Chin Pang resigned as finance director and company secretary and as authorised representative under Rule 3.05 of the Listing Rules and Part 16 of the Companies Ordinance, all effective 11 September 2026; executive director Mr. Lam Hiu Tung was appointed as acting finance director and Ms. Tsang Ai Yin as company secretary and authorised representative with effect from the same date.
On 10 September 2026, BCQ (01963.HK) announced that, with the approval of the People's Bank of China, its 2026 green financial bonds (first tranche) were bookbuilt on 8 September and completed issuance on 10 September 2026, comprising three-year fixed-rate bonds with an issuance size of RMB 5 billion and a coupon rate of 1.59%, with proceeds to fund green industry projects under the Green Finance Supported Projects Catalogue (2025 Edition).
On 10 September 2026, HUANENG POWER (00902.HK) announced the completion of its 2026 eleventh tranche of ultra-short-term financing bonds, with an issuance amount of RMB 2.5 billion, a term of 65 days, a unit face value of RMB 100 and a coupon rate of 1.33%, publicly issued in the national interbank bond market with Bank of Bohai and China Minsheng Bank as lead underwriters, with proceeds for working capital, debt structure adjustment and repayment of bank borrowings and maturing bonds.
On 10 September 2026, HATCHER GROUP (08365.HK) announced that all conditions precedent for the acquisition of a 51% equity interest in Hengrui Group Limited, to be satisfied by issuing consideration shares under a general mandate, have been fulfilled, with completion expected on 2 October 2026; the company had previously announced the discloseable transaction on 17 July and 4 September 2026.
On 10 September 2026, CHINA ORAL IND (08406.HK) announced that its subsidiary Shenzhen Heruijianheng entered into a joint venture agreement with Future Century (Shenzhen) Health Industry Holding to set up a joint venture in Shenzhen with registered capital of RMB 1,000,000, funded 51% by Heruijianheng with RMB 510,000 and 49% by Future Century with RMB 490,000, to principally engage in the sale of SOD synthetic biology health products; all applicable percentage ratios are below 5%, so the transaction is not a discloseable or connected transaction.
On 10 September 2026, WINOX (06838.HK) announced that its wholly-owned subsidiary Huizhou Fengcai entered into three agreements to dispose of an aggregate of 94 sets of used equipment at a total consideration of approximately RMB 15,111,504 (excluding VAT), against a total book value of approximately RMB 5,724,545.70, generating a gain of approximately RMB 9,386,958.72; aggregated with disposals to the same buyer of approximately RMB 2,149,628 in the preceding 12 months, the highest applicable percentage ratio exceeds 5% but is below 25%, making it a discloseable transaction exempt from shareholders' approval.
On 10 September 2026, MINIEYE (02431.HK) announced that Dr. Liu Guoqing, executive director, general manager and chairman, purchased 100,000 H shares on the open market at an average price of approximately HKD 2.3142 per share, representing approximately 0.02% of total issued shares; following the purchase he held 34,883,503 shares, or approximately 7.9% of total issued share capital, with concert parties holding approximately 17.62%.
On 10 September 2026, HUAQIN (03296.HK) announced that it completed the industrial and commercial registration change and obtained a renewed business licence from the Shanghai Municipal Administration for Market Regulation, with registered capital changed to RMB 1,515,803,032 and unified social credit code 91310115779776581R; the change was approved by the second board of directors at its 27th meeting on 26 June 2026.
